Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Selective inhibition of tyrosine kinase 2 (TYK2) may offer therapeutic promise in inflammatory conditions, with its role in downstream pro‐inflammatory cytokine signaling. In this first‐in‐human study, we evaluated the safety, tolerability, and pharmacokinetics (PK) of a novel TYK2 inhibitor, PF‐068...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ravi Shankar P. Singh (Autor), Vivek Pradhan (Autor), Erika S. Roberts (Autor), Matthew Scaramozza (Autor), Elizabeth Kieras (Autor), Jeremy D. Gale (Autor), Elena Peeva (Autor), Michael S. Vincent (Autor), Anindita Banerjee (Autor), Andrew Fensome (Autor), Martin E. Dowty (Autor), Peter Winkle (Autor), Christopher Tehlirian (Autor)
Formato: Libro
Publicado: Wiley, 2021-03-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible